LGALS9 and neoplasm: Our analysis identified a GALECTIN pathway present in these two T‐lineage tumours (Figure 4F), LGALS9 signals emitted from DN and DP cells interact with the HAVCR2 receptor on CD8+T cells and the CD44 receptor on Tregs.